The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...
Researchers have revealed critical insights into how impaired mitochondrial dynamics and quality control mechanisms in skeletal muscle influence insulin sensitivity in patients with Type 2 Diabetes, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results